Andrew Staron (@a_staron) header
Andrew Staron (@a_staron) profile picture

a.k.a. Amyloid Andrew. Newly minted hematologist at Boston University Medical Center. Former amyloid doc at the BU Amyloidosis Center. Hiking when I can.

Boston
Joined August 2018
Expert discussant panel at the #AmyloidosisForum with the @FDA - all committed to reliable scientific advancement in #Amyloidosis - including @vsanchorawala from @BU_Amyloidosis.
1
147
Isabelle Lousada and Kristen Hsu of @Amyloidosis_ARC kicking off the Amyloidosis Forum at the @FDA - accelerating drug development in amyloidosis.
2
130
Panel discussion - very engaged audience. @BU_Amyloidosis @omarsiddiqi @a_staron
1
6
427
Exciting day at @US_FDA brainstorming prognostic factors and clinical trial endpoints in AL Amyloidosis!
Dr. @rajshekharucms presenting the #AmyloidosisForum Prognostic Factors working group's plans to develop prognostic factors for clinical trial endpoints with quantitative assessments and validation that reflects current standards of care in #amyloidosis
3
8
63
6,066
As the event comes to a close, we want to express our gratitude to our dedicated multidisciplinary team members for sharing their research during the conference. #ISA2024 #Amyloidosis @ISA_Amyloidosis
7
45
2,646
💙Masterclass in Cardiac #Amyloidosis @MyASNC @NotNoninvasive @LPhillipsMD Day 1⃣⭐️ Prognostic markers in amyloidosis by Andrew Staron @a_staron @BU_Amyloidosis 👉ATTR
5
6
650
Andrew Staron retweeted
While we usually shrug it off as insignificant, the loss of the Y chromosome (mLOY) in men is associated with a much higher cancer mortality, CV mortality and all cause mortality than those without it. Possible association with ATTR amyloidosis. @BU_Amyloidosis
1
5
25
2,974
Significant and exciting news! Nexcella Announces FDA Approval of IND Application for CAR-T NXC-201. With this clearance, NEXICART-2 (NCT06097832) is to expand studies of NXC-201 in relapsed/refractory AL amyloidosis to the US. @BU_Amyloidosis nexcella.com/2023/11/21/nexc…
10
1
39
2,690
Increase awareness, decrease educational gap to diagnose early and improve outcomes. High clinical index of suspicion when red flag symptoms/signs/syndromes present is crucial.
Clinicians and scientists at the Boston University Amyloidosis Center continue research toward developing better treatments and a cure for amyloidosis. Join us in celebrating World Amyloidosis Day on October 26th.
1
8
1
25
2,692
Avoid implicit bias in amyloidosis & never skip genetic testing, particularly in minority groups. At @BU_Amyloidosis, 7 self-identified white patients with ATTRV122I and 19 self-identified Black patients with ATTRwt. The presentation of amyloidosis is truly diverse! @a_staron
2
8
35
2,732
February is Rare Disease Awareness Month! This month is all about public, medical, & political #amyloidosisawareness. Not only is it critical to let more people know about diagnostics and treatments that already exist but to create momentum for the development of new discoveries.
1
7
27
2,270
Do not start plasma cell directed therapies till diagnosis of AL Amyloidosis is confirmed by accurate identification of the precursor protein #ASH22 #amyloidosis @Amyloid_Planet
9
17
Save the date to hear from four of our incredible @BU_Amyloidosis clinicians during a live webinar hosted by @Amyloidosisfdn! Register for Updates in ATTR Cardiac and Neurological Amyloidosis at 12:00 pm ET on Friday, October 28 by visiting pathlms.com/amyloidosis/webi…
6
13
We're excited to share our report on apoptotic vulnerabilities in AL amyloidosis. We analyzed over 50 primary specimens from AL patients at @BU_Amyloidosis and find that clonal plasma cells are frequently dependent on BCL-2 or MCL-1 for survival. (1/n) nature.com/articles/s41467-0…
11
21
3
85
1/3:Absolutely need PYP or tissue to start treatment for cardiac #amyloidosis. There are many mimickers by both echo and CMR with variability in quality, technical issues, and interpretation in both, especially outside of amyloid centers.
Replying to @MarthaGrogan1
If the echo and MRI are consistent with amyloid (and AL excluded), is a PYP scan really needed prior to starting therapy? Is there data on diagnostic benefit on top of MRI? @BrettSperryMD
1
15
2
36
Home safe after a long day of travel! Thank you Heidelberg for showing your picturesque cobble streets and hospitality. Lots of great science to digest. But first, a morning run to burn off the week's schnitzels and potatoes. Missed you Boston!
11
Exciting meeting #ISA_2022. The future of diagnostics and therapeutics of Amyloidosis is bright with engagement of all stakeholders. Congratulations to Dr Schonland and @UHegenbart for organizing a very stimulating flawless meeting @BU_Amyloidosis
1
7
50
Great work by @SaelicesL determining multiple ATTR fibril structures #ISA_2022
1
8
1
30